German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

Ugur Sahin; Chief Executive Officer, Member of the Management Board; Biontech SE Oezlem Tuereci; Chief Medical Office, Member of the Management Board; Biontech SE Welcome to BioNTech's fourth quarter ...

BioNTech shares fell Monday, as the COVID-19 vaccine maker’s soft outlook offset better-than-expected quarterly results.

BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company ...

BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key ...

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

German biotech firm's revenues down 27% compared to 2023, according to company's financial report - Anadolu Ajansı ...

German biotech company BioNTech announced a financial loss of €665.3 million ($721 million) for 2024, attributing the decline ...

Freshfields represented Moderna, while Taylor Wessing advised BioNTech and Munich IP-firm df-mp was counsel to Pfizer.

A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna .

German biotech company BioNTech announced a loss of EURO665.3 million (USD721 million) in 2024, due to the decline of ...